Factors Driving Treatment Decision-Making in Frontline EGFR+ NSCLC

Samuel Rosner, MD, and Laura Alder, MD, discuss the clinical and molecular considerations that guide frontline treatment selection for patients with EGFR-mutated non–small cell lung cancer. Rosner highlights the importance of comprehensive molecular profiling to distinguish common EGFR alterations such as exon 19 deletions and exon 21 L858R mutations, as well as less common variants that may influence treatment selection. Alder emphasizes the role of additional clinical factors—including CNS involvement, patient comorbidities, disease burden, and patient preferences—in tailoring individualized treatment strategies.